Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

A new study found that dementia cases in the United States are projected to double from more than 500,000 in 2020 to about 1 million by 2050.

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

Calorie labels in supermarkets and restaurants have little impact on consumer choices, researchers found, fueling doubts ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

There are thousands of NAION sufferers. Recent studies have uncovered a frightening association between the popular diabetes and weight loss drugs, Ozempic and Wegovy, with a rare eye disorder ...

The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than Eli Lilly’s ...